Hogan Lovells is advising Novartis, a global pharmaceutical company, in a definitive agreement for the acquisition of Encore Vision, Inc. for an undisclosed amount.

Encore Vision is a privately-held company based in Fort Worth, Texas, that focuses on the development of a novel treatment in presbyopia. Presbyopia is a common age-related loss of near distance vision characterized by a progressive inability to focus on objects nearby. This acquisition would add a disease modifying topical treatment for presbyopia to the Novartis ophthalmology pipeline.

The transaction is subject to customary closing conditions, including regulatory approval.

Adam Golden and Michael Szlamkowicz are leading the Hogan Lovells team, which also includes Andrew Felton, Scott Grossman, and Jeff Jay. Scott Reisch and Marta Orpiszewska are offering environmental advice. Employee benefits and executive compensation counsel includes Marta Steinman, Michael Applebaum, and Adrienne Jack. Michael DeLarco and Elizabeth Seaver are advising on employment matters. Jeffrey Tolin and Catherine Chen is advising on tax. Robert Leibenluft and Leigh Oliver are representing on antitrust matters. Arlene Chow and Peter Noh are providing advice on intellectual property.